6535.TWO Lumosa Therapeutics Co. Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
70.00 TWD
Close of Nov 5, 2026
63.30 222.00
Market cap
TWD 11.7B
P/E
-
P/B
9.00x
ROE
-45.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6535.TWO undervalued?

Graham number

The Graham number of Lumosa Therapeutics Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lumosa Therapeutics Co. Ltd. fundamental analysis

No fundamental analysis for Lumosa Therapeutics Co. Ltd. yet.

Lumosa Therapeutics Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lumosa Therapeutics Co. Ltd.

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-c…

Full company profile